ClinicalTrials.gg
Not yet recruitingNCT07859423PreVailUpdated Oct 13, 2026

A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera

A Phase 2/3 interventional study of AG-236 and Placebo in Polycythemia Vera, sponsored by Agios Pharmaceuticals, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment

Updated Oct 13, 2026Eligibility revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial is a Phase 2/3 study that will determine the recommended dose and dose regimen of AG-236 and evaluate the efficacy, safety, and pharmacokinetics of AG-236 in polycythemia vera (PV) by testing how well AG-236 works compared to placebo to increase the number of subjects with no phlebotomy and absence of phlebotomy eligibility over a 13-week period. In addition, the long-term effect of AG-236 on efficacy and safety will be explored in an open-label extension portion.

Read the detailed description

AG-236 is a small interfering ribonucleic acid (siRNA) targeting transmembrane serine protease 6 (TMPRSS6) intended for the treatment of PV. The study aims to evaluate the efficacy and safety of treatment with AG-236 in subjects with PV. The study is a Phase 2/3 study in which the recommended dose and dose regimen of AG-236 will be selected and further evaluated. The Phase 2 portion includes a 26-week randomized, placebo-controlled period in which subjects will be randomized in a 1:1:1:1:1 ratio to receive 1 of 3 dose levels of AG-236 in 1 of 2 dose regimens or placebo. The Phase 3 portion includes a 26-week randomized, placebo-controlled period in which subjects will be randomized in a 2:1 ratio to receive the recommended AG-236 dose level and dose regimen or placebo. Subjects who complete either the Phase 2 or Phase 3 portion will have the option to move into a 104-week open-label extension period to receive AG-236.

02

Conditions studied

  • Polycythemia Vera

Browse trials for

03

In context

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

This study's planned enrollment of 245 is above the median of 52 across 204 interventional studies indexed under Polycythemia Vera.

Browse Polycythemia Vera studies →

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • PV diagnosis according to 2022 World Health Organization (WHO) criteria.
  • Phlebotomy requirements:

    • At least 3 documented phlebotomies in the 6 months before randomization or at least 5 documented phlebotomies in the 12 months before randomization; and
    • At least 1 documented phlebotomy within the 3 months before randomization.
    • No phlebotomy within 6 days before randomization (not including the day of phlebotomy and the day of randomization in the 6-day count).
  • Cytoreductive therapy is allowed at randomization, but the subject must be on a stable regimen for at least 2 months prior (or at least 6 months with interferons) with no planned change in cytoreductive dose.
  • Subjects on phlebotomy alone and no cytoreductive therapy at randomization must have stopped prior treatment at least 2 months prior (at least 6 months for interferons).

Key Exclusion Criteria:

  • Use of any or marketed N-acetylgalactosamine (GalNAc) targeting product less than 48 weeks before randomization or not recovered from effects of prior administration of any investigational or marketed GalNAc targeting product taken more than 48 weeks before randomization.
  • Currently receiving treatment with a hepcidin mimetic; the last dose must have been administered ≥6 months before randomization.
  • Currently receiving treatment with or history of any use of TMPRSS6 targeting molecules (antisense oligonucleotide [ASO], siRNA, antibodies) before randomization.
  • , active and/or uncontrolled hepatobiliary, renal, cardiac, or pulmonary disease.
  • Prior in the last 5 years, except for curatively treated basal cell carcinoma or non-melanoma skin tumors, curatively treated carcinoma in situ of the cervix or breast, or localized prostate cancer.
  • Clinically significant thrombosis within 2 months before randomization.
  • Meets the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
245 participants (estimated)

Study arms

  • Experimental
    Phase 2: AG-236 Dose X

    Subjects will receive AG-236 Dose X, administered subcutaneously (SC), according to the assigned dosing regimen, along with placebo administered SC as needed to maintain the blind in the double-blind period and will receive the same assigned AG-236 dose according to the protocol-defined regimen if they opt to participate in the extension period.

    Drug: AG-236 · Drug: Placebo

  • Experimental
    Phase 2: AG-236 Dose Y

    Subjects will receive AG-236 Dose Y, administered SC, according to the assigned dosing regimen, along with placebo administered SC as needed to maintain the blind in the double-blind period and will receive the same assigned AG-236 dose according to the protocol-defined regimen if they opt to participate in the extension period.

    Drug: AG-236 · Drug: Placebo

  • Experimental
    Phase 2: AG-236 Dose Z

    Subjects will receive AG-236 Dose Z, administered SC, according to the assigned dosing regimen, along with placebo administered SC as needed to maintain the blind in the double-blind period and will receive the same assigned AG-236 dose according to the protocol-defined regimen if they opt to participate in the extension period.

    Drug: AG-236 · Drug: Placebo

  • Experimental
    Phase 2: AG-236 Dose ZZ

    Subjects will receive AG-236 Dose ZZ, administered SC, according to the assigned dosing regimen in the double-blind period, and will receive the same assigned AG-236 dose according to the protocol-defined regimen if they opt to participate in the extension period.

    Drug: AG-236

  • Placebo comparator
    Phase 2: Placebo

    Subjects will receive placebo administered SC, according to the assigned dosing regimen in the double-blind period and will be randomized to receive AG-236 Dose X, Y, or Z if they opt to participate in the extension period.

    Drug: Placebo

  • Experimental
    Phase 3: AG-236

    Subjects will receive AG-236, administered SC at the dose and dose regimen selected for Phase 3 for 26 weeks in the double-blind period. Subjects who complete the double-blind period of the study will be eligible to continue receiving AG-236 in the open-label extension period.

    Drug: AG-236

  • Placebo comparator
    Phase 3: Placebo

    Subjects will receive placebo administered SC at the dose and dose regimen selected for Phase 3 for 26 weeks in the double-blind period. Subjects who complete the double-blind period of the study will be eligible to continue receiving AG-236 in the open-label extension period.

    Drug: Placebo

Interventions

  • DrugAG-236

    SC Injection

  • DrugPlacebo

    SC Injection

06

What researchers measure

Primary outcomes

  1. Phase 2 and Phase 3: Percentage of Subjects With No Phlebotomy and Absence of Phlebotomy Eligibility

    Time frame: Week 13 Through Week 26

Secondary outcomes

  1. Phase 2 and Phase 3: Number of Phlebotomies During the Double-blind Period

    Time frame: Up to Week 26

  2. Phase 2: Percentage of Subjects Achieving Hematocrit (HCT) Response During the Double-blind Period

    HCT response is defined as having at most one HCT assessment ≥45 percent (%) during the double-blind period.

    Time frame: Up to Week 26

  3. Phase 2 and Phase 3: Time to First HCT ≥45%

    Time frame: Up to Week 26

  4. Phase 2 and Phase 3: Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Week 130

  5. Phase 2 and Phase 3: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of AG-236

    Time frame: Each dose occasion from Day 1 to Week 52

  6. Phase 2 and Phase 3: Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of AG-236

    Time frame: Each dose occasion from Day 1 to Week 52

  7. Phase 2 and Phase 3: Maximum Observed Plasma Concentration (Cmax) of AG-236

    Time frame: Each dose occasion from Day 1 to Week 52

  8. Phase 2 and Phase 3: Percentage of Area Under the Concentration-Time Curve due to Extrapolation From the Last Quantifiable Concentration to Infinity (AUC%extrap) of AG-236

    Time frame: Each dose occasion from Day 1 to Week 52

  9. Phase 2 and Phase 3: Time to Last Measurable Concentration (tlast) of AG-236

    Time frame: Each dose occasion from Day 1 to Week 52

  10. Phase 2 and Phase 3: Time to Reach Maximum Observed Plasma Concentration (tmax) of AG-236

    Time frame: Each dose occasion from Day 1 to Week 52

  11. Phase 2 and Phase 3: Terminal Elimination Half-Life (t1/2) of AG-236

    Time frame: Each dose occasion from Day 1 to Week 52

  12. Phase 2 and Phase 3: Apparent Total Body Clearance (CL/F) of AG-236

    Time frame: Each dose occasion from Day 1 to Week 52

  13. Phase 2 and Phase 3: Apparent Volume of Distribution (Vz/F) of AG-236

    Time frame: Each dose occasion from Day 1 to Week 52

  14. Phase 3: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 8a T-score at Week 26

    Time frame: Baseline, Week 26

  15. Phase 3: Change From Baseline in PROMIS Fatigue SF 8a T-score at Week 26 Among Those who Have Fatigue at Baseline

    Time frame: Baseline, Week 26

  16. Phase 3: Percentage of Subjects With Improvement in the Patient Global Impression of Severity (PGIS) -Fatigue by at Least one Category at Week 26 Compared with Baseline or "No Change" if None or Mild Fatigue at Baseline

    Time frame: Baseline, Week 26

  17. Phase 3: Percentage of Subjects With Improvement in the Patient Global Impression of Change (PGIC) -Fatigue at Week 26 or "No Change" if None or Mild Fatigue at Baseline

    Time frame: Baseline, Week 26

  18. Phase 3: Change From Baseline in Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 Total Symptom Score at Week 26

    Time frame: Baseline, Week 26

  19. Phase 3: Change From Baseline in MFSAF v4.0 Total Symptom Score at Week 26 Among Those who Have Symptoms at Baseline

    Time frame: Baseline, Week 26

  20. Phase 3: Percentage of Subjects With Improvement in the PGIS-PV Symptoms by at Least 1 Category at Week 26 Compared With Baseline or "No Change" if None or Mild PV Symptoms at Baseline

    Time frame: Baseline, Week 26

  21. Phase 3: Percentage of Subjects With Improvement in the PGIC-PV Symptoms at Week 26 or "No Change" if None or Mild PV Symptoms at Baseline

    Time frame: Baseline, Week 26

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Aug 2030, 45 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 5, 2026
StartEst.
Nov 2026
Primary completionEst.
Aug 2030
CompletionEst.
Aug 2032
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 criterion edited, 1 removed
What changed in the criteria
  • EditedAt least 3 documented phlebotomies in the 6 months before randomization or at least 5 documented phlebotomies in the 12 months before randomization.; and
  • Removedand
Oct 13, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 13, 2026
    Eligibility 1 criterion edited, 1 removed
    What changed in the criteria
    • EditedAt least 3 documented phlebotomies in the 6 months before randomization or at least 5 documented phlebotomies in the 12 months before randomization.; and
    • Removedand
    + 1 other change: verification date
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859423
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Nov 2026 (estimated)
Primary completion
Aug 2030 (estimated)
Completion
Aug 2032 (estimated)
Last update
Oct 13, 2026

Study contacts

Agios Medical Affairs
Contact
medinfo@agios.com
08332288474

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion